Zentiva Polska

What Zentiva Polska does

Zentiva Polska Sp. z o.o. is the Polish operating subsidiary of Zentiva Group, a.s., a European pharmaceutical company that develops, manufactures, and distributes generic, biosimilar, and over-the-counter medicines across multiple therapeutic areas including cardiology, diabetology, pulmonology, oncology, neurology, gastroenterology, and urology. The Polish entity operates from its headquarters at 17 Bonifraterska Street, Warsaw, and is part of a broader group that serves more than 100 million patients in over 40 countries through 31 active subsidiaries, 6 branches, four owned manufacturing facilities, and an external production partner network. The group employs 5400+ people globally and 500+ in Poland, supported by a sales force of 1800+ medical representatives across Europe, with over 200 representatives operating in Poland.

Zentiva's core technology and operational backbone is a pharmaceutical Quality Management System aligned with ICH Q10 guidelines, supported by manufacturing facilities regularly inspected and approved by the EMA, MHRA, Swissmedic, and US FDA. The group's product portfolio includes prescription (Rx) generics, OTC medications, dietary supplements, biosimilars (developed in partnership with mAbxience and Lupin), and Consumer Healthcare products (recently expanded through the Aboca brands acquisition). Beyond finished-dose products, Zentiva monetizes its capabilities through two B2B platforms — Zent2U, which provides APIs, contract development and manufacturing (CDMO), and licensing services, and Prague Scientific, which offers formulation development, manufacturing, and pharmacovigilance services.

The business model is sales-led and diversified across multiple revenue streams: one-time sales of generic and OTC pharmaceuticals across 40+ European countries, professional services revenue from CDMO and development work, and licensing royalties. Go-to-market relies on direct engagement with physicians, pharmacists, and healthcare-system decision-makers through field sales representatives, complemented by pharmacy distribution partners and public tender procurement. Customer segments span healthcare professionals, retail and hospital pharmacies, public procurement agencies, distribution partners, and end patients. Pricing for prescription products is governed by national reimbursement systems across European markets, while OTC and B2B service pricing is determined by individual contract terms.

Name

Zentiva Polska

Legal name

Zentiva Polska Sp. z o.o.

Website

https://zentiva.pl

Company type

Private

Founded year

2003

Operating status

Operating

Short description

Zentiva Polska is the Polish subsidiary of Zentiva Group, a European pharmaceutical company developing, manufacturing, and distributing generic, biosimilar, and OTC medicines across cardiology, oncology, neurology, urology, and other therapeutic areas for patients in Poland and across Europe.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

Keywords

• Generic pharmaceuticals
• Over-the-counter medicines
• Biosimilar products
• Contract development manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices21 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals Sales: Core revenue from development, manufacturing and distribution of high-quality, affordable generic medicines across 40+ countries in Europe. Portfolio includes prescription (Rx) and over-the-counter (OTC) medications plus dietary supplements.
2. Contract Manufacturing (CDMO): Zent2U platform provides comprehensive B2B support including active pharmaceutical ingredients (API), contract development and manufacturing services, and licensing. Manufacturing capabilities offered through own facilities.
3. Licensing and Outlicensing: Licensing services through Zent2U and Prague Scientific platforms, offering development and scientific services supporting product lifecycle from concept to regulatory maintenance.
4. Consumer Healthcare Products: Portfolio of Consumer Healthcare products, particularly strengthened in Czech Republic, Romania, and Slovakia through Aboca brand acquisition.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

Zentiva Polska develops, markets, and supplies a broad portfolio of generic prescription (Rx) and over-the-counter (OTC) medicines, biosimilars, and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, respiratory, neurology, urology, and gastroenterology. As the Polish subsidiary of Zentiva Group, it distributes over 50 medicinal products in Poland through pharmacy and distribution partners, complemented by the group's B2B platforms (Zent2U for APIs, CDMO, and licensing; Prague Scientific for development services).

Product overview

Zentiva Polska is the Polish subsidiary of Zentiva Group, a leading European pharmaceutical company specializing in generic medicines, specialist products, and consumer healthcare. The company operates a unified portfolio combining prescription medications (Rx), over-the-counter products (OTC), and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, pulmonology, neurology, urology, and gastroenterology. The portfolio is complemented by B2B service platforms (Zent2U for API, CDMO, and licensing; Prague Scientific for development services) and patient support programs. The Polish operation distributes over 50 medicinal products, with the broader group serving over 100 million people in more than 40 countries through four manufacturing facilities and a network of production partners.

Differentiator

Problem solved

Functional benefit

Brands

• Zent2U: B2B business platform offering access to APIs, CDMO services, and licensing
• Prague Scientific
• Zentiva Stars

Products and services

• Generic Medicines Portfolio Broad portfolio of generic pharmaceuticals covering cardiovascular, oncology, respiratory, neurological, urological, musculoskeletal, and digestive therapeutic areas. Includes prescription (Rx) and over-the-counter (OTC) medications as well as dietary supplements available through pharmacy and distribution channels in Poland.
• Consumer Healthcare Products Portfolio of consumer healthcare products based on natural ingredients, including acquired Aboca brands. Distributed through retail pharmacy channels for direct consumer use.
• Added-Value Medicines Bioequivalent medicines and value-added solutions with modern formulations, integrating green design principles and new technologies for differentiated patient and prescriber value.
• Zent2U B2B Platform B2B platform offering access to active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, and out-licensing. Specializes in cardiology, urology, oncology, neurology, and hormone therapies for third-party pharmaceutical partners.
• Prague Scientific Development and scientific services supporting every stage of pharmaceutical product lifecycle from concept through regulatory maintenance, including active ingredient and formulation development, manufacturing in eco-friendly facilities, and pharmacovigilance activities.
• Patient Support Programs - Urology Educational programs for patients regarding benign prostatic hyperplasia (BPH), prostate cancer, and overactive bladder (OAB). Includes specialist consultations, knowledge assessments, and educational materials developed by experts.
• Zentiva dla Pacjenta - Patient Education Portal Patient-facing educational portal covering therapeutic areas including urology, psychiatry, neurology, cardiology, pulmonology, and allergology, with expert-authored articles and health guidance for Polish patients.

Quantifiable outcome

• 100 million+ people served across 40+ European countries
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered major, minor and core.

• LupinmajorStrategic or Co-development Partner · 9 July 2025License and supply agreement for a biosimilar TNF alpha inhibitor. Zentiva and Lupin collaboration expands biosimilar portfolio.
• AbocamajorStrategic or Co-development Partner · 1 January 2025Acquisition of recognized brands from Aboca strengthening Consumer Healthcare portfolio with natural ingredient-based products for consumers across Europe.
• AdalvomajorStrategic or Co-development Partner · 1 January 2023License agreement with Adalvo covering respiratory, CNS, and dermatology therapeutic areas.
• mAbxiencemajorStrategic or Co-development Partner · 1 January 2021First biosimilar product launch through collaboration with mAbxience. Product launched in 21 European countries.
• Creo Pharmaceuticals LtdmajorStrategic or Co-development Partner · 1 January 2019Acquisition of Creo Pharmaceuticals in United Kingdom expanding European presence.
• Solacium PharmamajorStrategic or Co-development Partner · 1 January 2019Acquisition of Solacium Pharma in Romania strengthening regional presence.
• Alvogen CEEmajorStrategic or Co-development Partner · 1 January 2019Acquisition of Alvogen operations in Central and Eastern Europe expanding generic pharmaceutical portfolio.
• PARC (Pharmaceutical Applied Research Centre)minorStrategic or Co-development PartnerAcademic collaboration through international research platform supporting pharmaceutical innovation and development.
• Medicines for EuropecoreOthersActive membership with participation in governance, supervisory board, and thematic groups. Applies Medicines for Europe Code of Conduct ensuring ethical marketing practices. Leading organization for generic pharmaceutical companies responsible for largest share of medicine deliveries in Europe.
• BusinessEuropeminorOthersMembership in Advisory and Support Group engaging in EU industrial policy shaping with focus on medicine production security and supply chains.
• Swiat Zdrowia S.A.minorStrategic or Co-development PartnerCampaign partner in 'Swiat w twoich rekach' (World in Your Hands) initiative for proper pharmaceutical waste disposal and patient adherence education. Part of NEUCA Group.
• Adamed PharmaminorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign alongside other leading Polish pharmaceutical companies.
• Teva Pharmaceuticals PolskaminorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign.
• Zaklady Farmaceutyczne Polpharma S.A.minorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Adamed Pharma: Polish private pharmaceutical group operating in generics, OTC and specialty. Comparable Polish-market positioning and a co-campaign partner with Zentiva in patient-adherence and disposal initiatives.
• Sandoz (Novartis): European-headquartered generics and biosimilars business spun out of Novartis. Closest direct competitor to Zentiva in European generics, with comparable geographic footprint, biosimilar portfolio and CDMO-style B2B service offering.
• Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with deep European commercial coverage. Highly comparable business model of high-volume generics plus selected specialty/biosimilar exposure, and similar reliance on tender and reimbursement channels across Europe.
• Viatris: Global generics and specialty pharma company formed from Mylan and Upjohn. Comparable generic-pharma economics, broad European presence, and growing biosimilars franchise that mirrors Zentiva's strategic direction.
• Stada Arzneimittel: Privately-held European generics and consumer healthcare company with strong German and CEE presence. Comparable portfolio mix of generics, OTC and biosimilars, and similar PE-ownership history.
• Gedeon Richter: Hungarian-origin specialty and generic pharmaceutical group with strong CEE footprint and European commercial reach. Comparable in generics plus specialty/biosimilar adjacency and CEE manufacturing base.
• Krka: Slovenian-headquartered generics manufacturer with leading Central and Eastern European market share. Highly comparable in therapeutic-area coverage, geographic mix and reliance on CEE tender markets.
• Polpharma: Poland's largest pharmaceutical manufacturer and a Zentiva co-campaign partner ('Świat w twoich rękach'). Directly competes with Zentiva Polska across generic and OTC categories in the Polish market.
• Alvogen: Central and Eastern European-focused generics group; Zentiva acquired Alvogen's CEE operations in 2019. Directly comparable product mix and CEE commercial footprint.

Emerging players

• Lupin: Indian-headquartered global generics and biosimilars manufacturer and Zentiva's biosimilar partner (TNF alpha inhibitor licensing deal). Comparable in biosimilar development and global generics ambitions, though with lower European commercial depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@zentiva
• LinkedInlinkedin.com/company/zentiva-polska

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries36 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentiva Polska